The story has not been an easy one to follow; even some of the seasoned biotech investors and first-rate contributors on this board have been unwilling to believe that Teva has been routinely misrepresenting the status of its Lovenox ANDA to the investment community. If even these people have been reluctant to acknowledge what Teva is doing, it’s easy to understand how less-informed investors are not yet getting it either.
<<Do you have any guesses as to why MNTA trades poorly?>>
Today's a real head scratcher.
With the "news" T's Italian partner plant was inspected Sept. 2010 My guess was MNTA had around 4 more months of adding $20 million per month to the $135 million already in the piggy bank until the gravy train went over the cliff.
With yesterday's WSJ "news" T had a problem in October 2010 the train may keep rolling.
Market Data 
Markets 
AI
